Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  AtriCure Inc.    ATRC

ATRICURE INC.

(ATRC)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

AtriCure : Announces Launch of the cryoICE® cryoSPHERE™ Probe

share with twitter share with LinkedIn share with facebook
share via e-mail
0
02/12/2019 | 08:01am EDT

cryoSPHERE probe launched in United States, designed exclusively for post-operative pain block

AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage management (LAAM), today announced that it has launched the cryoICE® cryoSPHERE probe in the United States. The cryoSPHERE probe is the first device in the cryoICE family solely dedicated to blocking pain by temporarily ablating peripheral nerves.

The cryoSPHERE probe offers a unique 8mm ball-tip design, a bendable distal shaft, and an ergonomic handle to provide cardiac, thoracic, and general surgeons ease of use when applying the device to the targeted peripheral nerves to block pain. The launch of the cryoSPHERE probe demonstrates AtriCure’s commitment to continued innovation in Cryo Nerve Block Therapy (cryoNB).

“The addition of the cryoSPHERE probe to our pain management portfolio is a major breakthrough in cardiac and thoracic surgery,” said Mike Carrel, President and Chief Executive Officer. “cryoSPHERE is the first of its kind, designed specifically to freeze nerves in the chest wall. With cryoSPHERE, surgeons can use cryoNB therapy to reduce their patients’ post-operative pain.”

The cryoSPHERE technology uses a unique freezing method to temporarily block nerves from transmitting pain signals. The block typically lasts several months, during which time the nerve regenerates, giving the body time to heal. Because of the long-lasting nature of the therapy, physicians are adopting cryoNB as an adjunct to their pain management modalities, offering a unique solution for patients undergoing cardiothoracic surgery.

“Since incorporating the technique of a cryoNB in my thoracic surgical practice several years ago, I have seen a remarkable improvement in overall management of post-operative pain, post-operative recovery times, and patient satisfaction,” said Dr. Curtis Quinn, Cardiothoracic Surgeon, Elliott Health System, Manchester, NH. “The cryoSPHERE probe is an impressive new tool dedicated to managing pain in patients undergoing cardiothoracic surgery.”

About AtriCure, Inc.

AtriCure, Inc. provides innovative technologies for the treatment of Afib and related conditions. Afib affects more than 33 million people worldwide. Electrophysiologists and cardiothoracic surgeons around the globe use AtriCure technologies for the treatment of Afib and reduction of Afib related complications. AtriCure’s Isolator® Synergy™ Ablation System is the first and only medical device to receive FDA approval for the treatment of persistent Afib. AtriCure’s AtriClip Left Atrial Appendage (LAA) Exclusion System products are the most widely sold LAA management devices worldwide, with more than 170,000 implanted to date. For more information, visit AtriCure.com or follow us on Twitter @AtriCure.


© Business Wire 2019
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ATRICURE INC.
04/04ATRICURE : to Announce First Quarter 2019 Financial Results
BU
04/01ATRICURE : to Present at the Needham & Company's 18th Annual Healthcare Conferen..
BU
03/01ATRICURE : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESUL..
AQ
02/28ATRICURE, INC. : Results of Operations and Financial Condition, Financial Statem..
AQ
02/28ATRICURE : Reports Fourth Quarter and Full Year 2018 Financial Results
BU
02/19ATRICURE : Announces The Society of Thoracic Surgeons Has Endorsed the Company's..
BU
02/16ATRICURE : First patient enrolled in ICE-AFIB clinical trial
AQ
02/12ATRICURE : Announces Launch of the cryoICE® cryoSPHERE™ Probe
BU
02/09ATRICURE : treats first Afib patient with cryoICE Ablation System
AQ
02/07ATRICURE : ATRC) Reports First Patient Enrollment in ICE-AFIB Clinical Trial
AQ
More news
Financials ($)
Sales 2019 226 M
EBIT 2019 -25,6 M
Net income 2019 -26,5 M
Finance 2019 36,0 M
Yield 2019 -
P/E ratio 2019 -
P/E ratio 2020
EV / Sales 2019 4,48x
EV / Sales 2020 3,91x
Capitalization 1 049 M
Chart ATRICURE INC.
Duration : Period :
AtriCure Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ATRICURE INC.
Short TermMid-TermLong Term
TrendsNeutralBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 7
Average target price 37,8 $
Spread / Average Target 39%
EPS Revisions
Managers
NameTitle
Michael H. Carrel President, Chief Executive Officer & Director
Scott William Drake Chairman
Douglas J. Seith Chief Operating Officer
M. Andrew Wade CFO, Principal Accounting Officer & Senior VP
Vini Doraiswamy SVP-Clinical, Regulatory & Scientific Affairs
Sector and Competitors
1st jan.Capitalization (M$)
ATRICURE INC.-11.31%1 049
MEDTRONIC PLC-7.41%112 952
BAXTER INTERNATIONAL INC.12.93%37 991
HOYA CORPORATION15.07%25 320
ZIMMER BIOMET HOLDINGS15.70%24 550
ALIGN TECHNOLOGY34.41%22 518